drugset / Trial / NCT05969158
Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
To explore the efficacy and safety of hetrombopag for secondary prevention of thrombocytopenia caused by XPO-1 inhibitor Selinexor combined with chemotherapy in patients with lymphoma.
Timeline
- Start
- 2023-09-04
- Primary completion
- 2025-05-01
- Completion
- 2025-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hetrombopag | Small molecule | 5 mg | Oral |